LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis.

    Sodani, Pietro / Mucci, Luciano / Girolimetti, Rita / Tedesco, Silvia / Monaco, Francesca / Campanozzi, Daniele / Brunori, Marino / Maltoni, Stefania / Bedetta, Samuele / Di Carlo, Anna M / Candoli, Piero / Mancini, Mauro / Rebonato, Alberto / D'Adamo, Francesca / Capalbo, Maria / Frausini, Gabriele

    Respiratory medicine case reports

    2020  Volume 31, Page(s) 101115

    Abstract: The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health. In the current paper, we describe our successful treatment of one COVID-19 ... ...

    Abstract The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health. In the current paper, we describe our successful treatment of one COVID-19 pneumonia patient case with high mortality risk factors. Our experience underlines the importance of the use of a multidisciplinary therapeutic approach in order to achieve a favorable clinical outcome. Further, enhancing the capability of the COVID-19 diagnosis with the use of the chest imaging modalities is discussed.
    Keywords covid19
    Language English
    Publishing date 2020-06-27
    Publishing country England
    Document type Case Reports
    ZDB-ID 2666110-X
    ISSN 2213-0071
    ISSN 2213-0071
    DOI 10.1016/j.rmcr.2020.101115
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report

    Sodani, Pietro / Mucci, Luciano / Girolimetti, Rita / Tedesco, Silvia / Monaco, Francesca / Campanozzi, Daniele / Brunori, Marino / Maltoni, Stefania / Bedetta, Samuele / Di Carlo, Anna M. / Candoli, Piero / Mancini, Mauro / Rebonato, Alberto / D'Adamo, Francesca / Capalbo, Maria / Frausini, Gabriele

    Respiratory medicine case reports, 31:101115

    Review of treatments and clinical role of computed tomography analysis

    2020  

    Abstract: The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health. In the current paper, we describe our successful treatment of one COVID-19 ... ...

    Abstract The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health. In the current paper, we describe our successful treatment of one COVID-19 pneumonia patient case with high mortality risk factors. Our experience underlines the importance of the use of a multidisciplinary therapeutic approach in order to achieve a favorable clinical outcome. Further, enhancing the capability of the COVID-19 diagnosis with the use of the chest imaging modalities is discussed.
    Keywords COVID-19 ; Viral pneumonia ; SARS-CoV-2 ; Coronavirus ; covid19
    Language English
    Publishing country de
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report

    Sodani, Pietro / Mucci, Luciano / Girolimetti, Rita / Tedesco, Silvia / Monaco, Francesca / Campanozzi, Daniele / Brunori, Marino / Maltoni, Stefania / Bedetta, Samuele / Di Carlo, Anna M. / Candoli, Piero / Mancini, Mauro / Rebonato, Alberto / D'Adamo, Francesca / Capalbo, Maria / Frausini, Gabriele

    Respiratory Medicine Case Reports

    Review of treatments and clinical role of computed tomography analysis

    2020  Volume 31, Page(s) 101115

    Keywords Pulmonary and Respiratory Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2666110-X
    ISSN 2213-0071
    ISSN 2213-0071
    DOI 10.1016/j.rmcr.2020.101115
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.

    Mele, Anna / Sparaventi, Giovanni / Guiducci, Barbara / Nicolini, Giuseppina / d'Adamo, Francesca / Leopardi, Giuliana / Delfini, Costante / Piccaluga, Pierpaolo / Visani, Giuseppe

    Haematologica

    2004  Volume 89, Issue 6 Suppl, Page(s) ECR18

    MeSH term(s) Aged ; Aminoglycosides/administration & dosage ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cytarabine/administration & dosage ; Female ; Humans ; Immunotoxins/administration & dosage ; Leukemia, Myeloid, Acute/drug therapy ; Salvage Therapy ; Treatment Outcome
    Chemical Substances Aminoglycosides ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Immunotoxins ; Cytarabine (04079A1RDZ) ; gemtuzumab (93NS566KF7)
    Language English
    Publishing date 2004-06-01
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study.

    Visani, Giuseppe / Ferrara, Felicetto / Alesiani, Francesco / Ronconi, Sonia / Catarini, Massimo / D'adamo, Francesca / Guiducci, Barbara / Bernardi, Daniele / Barulli, Sara / Piccaluga, Pierpaolo / Rocchi, Marco / Isidori, Alessandro

    Leukemia & lymphoma

    2008  Volume 49, Issue 6, Page(s) 1081–1086

    Abstract: We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. Twenty frail ... ...

    Abstract We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. Twenty frail patients (median age, 73 years), as defined by Balducci et al., with diffuse large B cell or grade IIIb follicular lymphoma, either at diagnosis (15 patients) or relapsed (five patients), were prospectively enrolled. Nine out of 20 (45%) had a World Health Organisation (WHO) performance status > or =2. Fifteen out of 20 patients (75%) had an International Prognostic Index (IPI) score > or =3. Thirteen out of 20 (65%) evaluable patients obtained a complete response. Five additional patients (25%) achieved a partial response. With a median follow-up of 24 months (range 18-27), 15/18 responding patients (83%) are alive and disease free, as well as 3/18 are alive with active disease. Toxicity was mainly hematological with grade 3/4 neutropenia in 26% of cycles and febrile neutropenia in 5%. However, 3/20 patients presented a grade III-IV WHO toxicity (one fatal pulmonary embolism, one congestive, and one ischemic heart failure) while receiving R-COMP chemotherapy. In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma.
    MeSH term(s) Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Frail Elderly ; Humans ; Lymphoma, Follicular/drug therapy ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Male ; Maximum Tolerated Dose ; Middle Aged ; Pilot Projects ; Prednisone/administration & dosage ; Prognosis ; Prospective Studies ; Rituximab ; Treatment Outcome ; Vincristine/administration & dosage
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Murine-Derived ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2008-05-02
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428190802043853
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab.

    Visani, Giuseppe / Mele, Anna / Guiducci, Barbara / D'Adamo, Francesca / Leopardi, Giuliana / Barulli, Sara / Malerba, Lara / Lucesole, Moira / Sparaventi, Giovanni / Piccaluga, Pier Paolo / Guernaccini, Elena / Agostinelli, Fabrizio / Isidori, Alessandro

    Leukemia & lymphoma

    2006  Volume 47, Issue 12, Page(s) 2542–2546

    Abstract: Fifteen consecutive resistant/relapsed chronic lymphocytic leukemia (CLL) patients (median age: 65 years) received alemtuzumab for 16 consecutive weeks. All patients had negative CMV anti genemia at baseline. Five patients received oral acyclovir 800 mg ... ...

    Abstract Fifteen consecutive resistant/relapsed chronic lymphocytic leukemia (CLL) patients (median age: 65 years) received alemtuzumab for 16 consecutive weeks. All patients had negative CMV anti genemia at baseline. Five patients received oral acyclovir 800 mg twice a day for CMV prophylaxis and 10 patients got intravenous (iv) ganciclovir 7.5 mg/kg once a week. A total of five CMV reactivations occurred, four in the acyclovir and one in the ganciclovir prophylaxis group. Alemtuzumab was then discontinued and all patients were treated with iv ganciclovir 7.5 mg/kg per day. All patients achieved negative CMV anti genemia after a median of 15 days of therapy. Weekly iv ganciclovir prophylaxis and alemtuzumab treatment were then restarted without any further CMV reactivations. In conclusion, weekly iv ganciclovir appears feasible and effective in preventing CMV reactivation and disease in this setting of high-risk immunocompromised patients, allowing an easier management of a therapy otherwise difficult to be routinely used.
    MeSH term(s) Aged ; Alemtuzumab ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal, Humanized ; Antibodies, Neoplasm/administration & dosage ; Antiviral Agents/therapeutic use ; Cytomegalovirus Infections/complications ; Cytomegalovirus Infections/prevention & control ; Female ; Ganciclovir/administration & dosage ; Humans ; Immune System/pathology ; Infusions, Intravenous ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Male ; Middle Aged ; Time Factors ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antibodies, Neoplasm ; Antiviral Agents ; Alemtuzumab (3A189DH42V) ; Ganciclovir (P9G3CKZ4P5)
    Language English
    Publishing date 2006-11-30
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428190600929311
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.

    Mele, Anna / Leopardi, Giuliana / Sparaventi, Giovanni / Nicolini, Giuseppina / D'Adamo, Francesca / Guiducci, Barbara / Barulli, Sara / Malerba, Lara / Stramigioli, Stefania / Talevi, Nadia / Politi, Patrizia / Isidori, Alessandro / Malagola, Michele / Piccaluga, Pierpaolo / Visani, Giuseppe

    European journal of haematology

    2005  Volume 74, Issue 4, Page(s) 277–281

    Abstract: Fludarabine-based cycles severely impair mobilisation and collection of peripheral blood stem cells (PBSC) in acute myeloid leukaemia (AML). In an effort of reversing this side-effect, we studied the action on mobilisation and collection of PBSC of a low- ...

    Abstract Fludarabine-based cycles severely impair mobilisation and collection of peripheral blood stem cells (PBSC) in acute myeloid leukaemia (AML). In an effort of reversing this side-effect, we studied the action on mobilisation and collection of PBSC of a low-dose regimen: 5-d Mini-ICE (oral idarubicin and etoposide; subcutaneous cytosine arabinoside) administered after fludarabine-based regimens in seven adult AML patients. Leukapheresis were started when the CD34+ cell count was more than 10/microL. The median number of harvested CD34+ cells was 8.1 x 10(6)/kg (range 3.08-15.2). All the patients were successfully submitted to PBSC transplantation. Median times to neutrophil and platelet recovery were rapid with a normal transfusional support. We suggest that the Mini-ICE programme is feasible, well tolerated and effective in terms of PBSC mobilisation and collection in low-yield AML patients previously treated with fludarabine. It is well known that a negative effect on stem cell mobilisation and harvest is observed not only after fludarabine administration in AML or low-grade lymphomas, but also after cycles based on different agents, such as thalidomide in multiple myeloma. This preliminary experience, if confirmed on larger series and/or other haematological malignancies, could open new opportunities to perform autologous PBSC transplantation in heavily pretreated cases, allowing a full source of therapeutic options before the start of the mobilisation process.
    MeSH term(s) Adult ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Cytarabine/administration & dosage ; Etoposide/administration & dosage ; Female ; Hematopoietic Stem Cell Mobilization/methods ; Humans ; Idarubicin/administration & dosage ; Leukapheresis ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Peripheral Blood Stem Cell Transplantation ; Transplantation, Autologous ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/analogs & derivatives
    Chemical Substances Cytarabine (04079A1RDZ) ; Etoposide (6PLQ3CP4P3) ; Vidarabine (FA2DM6879K) ; fludarabine (P2K93U8740) ; Idarubicin (ZRP63D75JW)
    Language English
    Publishing date 2005-04
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/j.1600-0609.2004.00383.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 323: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top